BioNTech (22UA) Stock Overview
A biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
22UA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BioNTech SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$81.04 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 1.31 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -15.69% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -5.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 22UA | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | -3.5% | -1.3% | -0.2% |
| 1Y | -15.7% | 7.5% | 3.4% |
Return vs Industry: 22UA underperformed the Swiss Biotechs industry which returned 7.5% over the past year.
Return vs Market: 22UA underperformed the Swiss Market which returned 3.4% over the past year.
Price Volatility
| 22UA volatility | |
|---|---|
| 22UA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in CH Market | 7.3% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: 22UA's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine 22UA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 6,772 | Ugur Sahin | www.biontech.de |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor.
BioNTech SE Fundamentals Summary
| 22UA fundamental statistics | |
|---|---|
| Market cap | CHF 19.97b |
| Earnings (TTM) | -CHF 532.19m |
| Revenue (TTM) | CHF 2.94b |
Is 22UA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 22UA income statement (TTM) | |
|---|---|
| Revenue | €3.15b |
| Cost of Revenue | €552.00m |
| Gross Profit | €2.60b |
| Other Expenses | €3.17b |
| Earnings | -€571.60m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 10, 2026
| Earnings per share (EPS) | -2.38 |
| Gross Margin | 82.49% |
| Net Profit Margin | -18.13% |
| Debt/Equity Ratio | 0.2% |
How did 22UA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/09 10:18 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioNTech SE is covered by 35 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harry Gillis | Berenberg |
| Zhiqiang Shu | Berenberg |
| Evan Seigerman | BMO Capital Markets Equity Research |